Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA - AJAX

Study identifier:D8210C00003

ClinicalTrials.gov identifier:NCT06020014

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

Medical condition

asthma

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD4604

Sex

All

Estimated Enrollment

320

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 16 Nov 2023
Estimated Primary Completion Date: 30 Sept 2025
Estimated Study Completion Date: 30 Sept 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria